Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule…
Right now, there are a number of therapeutic options for people living with Waldenstrom macroglobulinemia (WM), such as chemotherapy, immunotherapy, radiation, plasmapheresis, stem cell transplantation, and targeted therapy. However, these…
According to a story from AJMC, a recent critical review evaluated the class of therapies known as Bruton tyrosine kinase (BTK) inhibitors and their use in the treatment of Waldenström's…
According to a recent article, the trial studying the success of CLR 131 to treat Waldenstrom’s macroglobulinemia has shown promising results, allowing it to continue. Waldenstrom Macroglobulinemia (WM) Waldenstrom macroglobulinemia…
On March 29, 2022, the International Waldenström's Macroglobulinemia Foundation (IWMF) hosted a webinar titled "An Overview of Amyloidosis and WM with Dr. Morie Gertz." The goal of this program was…
According to an article from MedPage Today, Waldenström's macroglobulinemia (WM) is a rare form of lymphoma. Only about 1,500 cases are diagnosed each year in the US. In this story,…
According to a press release from Business Wire, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recently issued a positive opinion in regards to the…
The FDA has just announced their approval of zanubrutinib (Brukinsa) as a therapeutic option for Waldenström's macroglobulinemia. This approval was given based on the ASPEN Phase 3 clinical trial, and…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) recently held the latest webinar in its Global Education series on July 9, 2021. This webinar was a summary of research presented at the…
On May 4th The International Waldenstrom's Macroglobulinemia Foundation (IWMF) held another webinar in its 2021 IWMF Global Education series titled Peripheral Neuropathy: No Easy Feat. As the title implies, the…
Recently the Leukemia & Lymphoma Society (LLS), in coordination with the International Waldenstrom's Macroglobulinemia Foundation (IWMF), hosted its Waldenström's Macrogloblinemia (WM) Patient Education Program webinar on April 7th, 2021. Patient…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) recently hosted a webinar presentation on February 9, 2021. This webinar, titled "Why Clinical Trials Matter and How to Find the Right One for…
2021 IWMF GLOBAL EDUCATIONAL WEBINAR Why Clinical Trials Matter and How to Find the Right One for You February 9th, 2021 Featuring Neena Kennedy, RN, BSN, OCN Clinical trials are…
According to a story from newswise.com, a team of researchers from the University of New Hampshire may have discovered the next new treatment for a rare form of blood cancer…
In late December 2020, biopharmaceutical company AbbVie announced via press release that the prescribing information for IMBRUVICA (ibrutinib) is now updated to include long-term safety and efficacy data for…
On October 14th, 2020, the International Waldenström's Macroglobulinemia Foundation (IWMF) hosted a webinar featuring Dr. Irene Ghobrial of the Dana Farber Cancer Institute. The focus of her presentation was on…
2020 IWMF Global Education Webinar IgM MGUS & Smoldering WM: How Understanding Precursors Can Help in Finding a Cure with Dr. Irene Ghobrial The International Waldenstrom's Macroglobulinemia Foundation (IWMF) encourages…
September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…
In a recent webinar hosted by the International Waldenström's Macroglobulinemia Foundation (IWMF) and held on July 22nd, 2020, Dr. Jeffery Matous from the Colorado Blood Cancer Institute gave an in-depth…
According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US Food and Drug Administration (FDA).…
A new study is seeking to understand how the ongoing coronavirus/COVID-19 pandemic is impacting patients with a rare blood cancer called Waldenström's macroglobulinemia (WM). The research is to be conducted…
The International Waldenstrom's Macroglobulinemia Foundation and CancerCare's Connect Education Workshop: "For Caregivers: Coping with a Loved One's WM" January 10th, 2020 from 1:30-2:30 pm This workshop will be geared towards…
According to an announcement from the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the organization has recently added a new fact sheet to their website. This fact sheet is focused on the…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) has recently announced an exciting new partnership that will help facilitate spreading awareness about Waldenstrom's macroglobulinemia (WM), a rare form of blood cancer. This…
Anita Lawson was paying the doctor a visit for her annual checkup in 2003 when she was told something that surprised her: she had anemia. She had some issues with…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
